Topical losartan at 0.8 mg/mL for nebulo-macular corneal opacities: A case series
Kerala Journal of Ophthalmology · 2026-01 · 38 (1) · 73-77
DOI: 10.4103/kjo.kjo_75_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kerala Journal of Ophthalmology, online erschienen am 06.04.2026. Verfasst von Faheem Raja und 1 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Nebulo-macular stromal corneal opacities from healed keratitis or trauma can cause persistent visual impairment. Preclinical data suggest that topical losartan inhibits Transforming Growth factor (TGF)-β–mediated fibrosis and reduces corneal scarring. We report a prospective case series of four patients with stable nebulo-macular opacities treated with topical losartan at 0.8 mg/mL, following the CARE guidelines for enhancing transparency and reproducibility. Case Presentations: Four adult patients (2 men, 2 women; mean age = 49.8 ± 16.9 years) with stable nebulo-macular corneal opacities ≥ 6 months (aetiologies: healed keratitis or trauma) received compounded topical losartan at 0.8 mg/mL; losartan was administered at one drop six times daily for 3 months. Monthly assessments included ETDRS BCVA (converted to LogMAR), slit-lamp examination, intraocular pressure (IOP), ocular surface tests, systemic blood pressure, and AS-OCT imaging with the en face opacity area measured in ImageJ by two masked graders. Baseline opacity areas ranged from 170 to 272 mm 2 ; at 3 months, the areas decreased by 33.0%–70.6% (mean reduction = 53.4% ± 16.5%). In three eyes, BCVA improved by 0.12–0.42 LogMAR; one remained stable. No ocular or systemic adverse events occurred.
Discussion
This small series demonstrates substantial opacity reduction and modest visual gains after losartan treatment, aligning with preclinical TGF-β inhibition data and previous case reports. Detailed methodology (formulation, imaging protocols, measurement reproducibility, safety monitoring) is provided to inform future controlled trials. Limitations include small sample size, lack of a control group, heterogeneity, short follow-up, and manual measurement subjectivity.
Conclusion
Topical losartan at 0.8 mg/mL administered for 3 months was well-tolerated and associated with a marked reduction in the nebulo-macular opacity area and modest improvement in BCVA. The detailed protocol may guide the design of future clinical trials to confirm efficacy and safety.
Zitieren
APA
Raja, F., & Hemalatha, K. (2026). Topical losartan at 0.8 mg/mL for nebulo-macular corneal opacities: A case series. Kerala Journal of Ophthalmology, 38(1), 73-77. https://doi.org/10.4103/kjo.kjo_75_25
Vancouver
Raja F, Hemalatha K. Topical losartan at 0.8 mg/mL for nebulo-macular corneal opacities: A case series. Kerala Journal of Ophthalmology. 2026;38(1):73-77. doi:10.4103/kjo.kjo_75_25
BibTeX
@article{Raja2026,
author = {Raja, Faheem and Hemalatha, Karri},
title = {Topical losartan at 0.8 mg/mL for nebulo-macular corneal opacities: A case series},
journal = {Kerala Journal of Ophthalmology},
year = {2026},
volume = {38},
number = {1},
pages = {73--77},
doi = {10.4103/kjo.kjo_75_25}
}
EUVIMED